Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review.
MIPD
eHealth
mHealth
mobile apps
model-informed precision dosing
smartphone
therapeutic drug monitoring
tuberculosis
video observed treatment
Journal
JMIR mHealth and uHealth
ISSN: 2291-5222
Titre abrégé: JMIR Mhealth Uhealth
Pays: Canada
ID NLM: 101624439
Informations de publication
Date de publication:
21 04 2020
21 04 2020
Historique:
received:
29
11
2019
accepted:
22
02
2020
revised:
10
02
2020
entrez:
22
4
2020
pubmed:
22
4
2020
medline:
28
4
2021
Statut:
epublish
Résumé
Mobile health (mHealth) is a rapidly emerging market, which has been implemented in a variety of different disease areas. Tuberculosis remains one of the most common causes of death from an infectious disease worldwide, and mHealth apps offer an important contribution to the improvement of tuberculosis treatment. In particular, apps facilitating dose individualization, adherence monitoring, or provision of information and education about the disease can be powerful tools to prevent the development of drug-resistant tuberculosis or disease relapse. The aim of this review was to identify, describe, and categorize mobile and Web-based apps related to tuberculosis that are currently available. PubMed, Google Play Store, Apple Store, Amazon, and Google were searched between February and July 2019 using a combination of 20 keywords. Apps were included in the analysis if they focused on tuberculosis, and were excluded if they were related to other disease areas or if they were games unrelated to tuberculosis. All apps matching the inclusion criteria were classified into the following five categories: adherence monitoring, individualized dosing, eLearning/information, diagnosis, and others. The included apps were then summarized and described based on publicly available information using 12 characteristics. Fifty-five mHealth apps met the inclusion criteria and were included in this analysis. Of the 55 apps, 8 (15%) were intended to monitor patients' adherence, 6 (11%) were designed for dosage adjustment, 29 (53%) were designed for eLearning/information, 3 (6%) were focused on tuberculosis diagnosis, and 9 (16%) were related to other purposes. The number of mHealth apps related to tuberculosis has increased during the past 3 years. Although some of the discovered apps seem promising, many were found to contain errors or provided harmful or wrong information. Moreover, the majority of mHealth apps currently on the market are focused on making information about tuberculosis available (29/55, 53%). Thus, this review highlights a need for new, high-quality mHealth apps supporting tuberculosis treatment, especially those supporting individualized optimized treatment through model-informed precision dosing and video observed treatment.
Sections du résumé
BACKGROUND
Mobile health (mHealth) is a rapidly emerging market, which has been implemented in a variety of different disease areas. Tuberculosis remains one of the most common causes of death from an infectious disease worldwide, and mHealth apps offer an important contribution to the improvement of tuberculosis treatment. In particular, apps facilitating dose individualization, adherence monitoring, or provision of information and education about the disease can be powerful tools to prevent the development of drug-resistant tuberculosis or disease relapse.
OBJECTIVE
The aim of this review was to identify, describe, and categorize mobile and Web-based apps related to tuberculosis that are currently available.
METHODS
PubMed, Google Play Store, Apple Store, Amazon, and Google were searched between February and July 2019 using a combination of 20 keywords. Apps were included in the analysis if they focused on tuberculosis, and were excluded if they were related to other disease areas or if they were games unrelated to tuberculosis. All apps matching the inclusion criteria were classified into the following five categories: adherence monitoring, individualized dosing, eLearning/information, diagnosis, and others. The included apps were then summarized and described based on publicly available information using 12 characteristics.
RESULTS
Fifty-five mHealth apps met the inclusion criteria and were included in this analysis. Of the 55 apps, 8 (15%) were intended to monitor patients' adherence, 6 (11%) were designed for dosage adjustment, 29 (53%) were designed for eLearning/information, 3 (6%) were focused on tuberculosis diagnosis, and 9 (16%) were related to other purposes.
CONCLUSIONS
The number of mHealth apps related to tuberculosis has increased during the past 3 years. Although some of the discovered apps seem promising, many were found to contain errors or provided harmful or wrong information. Moreover, the majority of mHealth apps currently on the market are focused on making information about tuberculosis available (29/55, 53%). Thus, this review highlights a need for new, high-quality mHealth apps supporting tuberculosis treatment, especially those supporting individualized optimized treatment through model-informed precision dosing and video observed treatment.
Identifiants
pubmed: 32314977
pii: v8i4e17246
doi: 10.2196/17246
pmc: PMC7201317
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17246Informations de copyright
©Lina Keutzer, Sebastian G Wicha, Ulrika SH Simonsson. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 21.04.2020.
Références
CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):785-787
pubmed: 30255663
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Br J Clin Pharmacol. 2019 Jun;85(6):1326-1336
pubmed: 30767254
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6698-6702
pubmed: 27572411
Eur Respir J. 2018 Nov 1;52(5):
pubmed: 30166325
Br J Clin Pharmacol. 2019 Oct;85(10):2436-2441
pubmed: 31313335
Clin Microbiol Infect. 2019 Oct;25(10):1286.e1-1286.e7
pubmed: 30872102
Clin Pharmacol Ther. 2017 May;101(5):646-656
pubmed: 28182269
Clin Pharmacol Ther. 1979 Sep;26(3):294-305
pubmed: 466923
Clin Infect Dis. 2016 Oct 1;63(7):e147-e195
pubmed: 27516382
Clin Pharmacokinet. 2013 Jan;52(1):9-22
pubmed: 23196713
J Infect Dis. 2013 Nov 1;208(9):1464-73
pubmed: 23901086
JMIR Mhealth Uhealth. 2016 May 13;4(2):e25
pubmed: 27177591
Am J Prev Med. 2010 Jul;39(1):78-80
pubmed: 20537846
JMIR Mhealth Uhealth. 2015 Mar 11;3(1):e27
pubmed: 25760773
Int J Antimicrob Agents. 2015 Apr;45(4):442-4
pubmed: 25631677
Int J Tuberc Lung Dis. 2015 Sep;19(9):1057-64
pubmed: 26260824
Lancet. 2019 Mar 23;393(10177):1216-1224
pubmed: 30799062
J Cheminform. 2013 Mar 06;5(1):13
pubmed: 23497706
Int J Tuberc Lung Dis. 2016 May;20(5):588-93
pubmed: 27084810
J Clin Tuberc Other Mycobact Dis. 2019 Feb 08;15:100093
pubmed: 31720420